X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (273) 273
Publication (30) 30
Book Review (7) 7
Book Chapter (4) 4
Conference Proceeding (3) 3
Newspaper Article (3) 3
Newsletter (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
bosutinib (273) 273
index medicus (142) 142
humans (129) 129
dasatinib (126) 126
imatinib (117) 117
nilotinib (96) 96
chronic myeloid leukemia (92) 92
oncology (92) 92
chronic myelogenous leukemia (60) 60
hematology (60) 60
tyrosine kinase inhibitors (60) 60
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (59) 59
tyrosine kinase inhibitor (58) 58
leukemia (56) 56
chronic myeloid-leukemia (54) 54
female (53) 53
protein kinase inhibitors - therapeutic use (51) 51
male (48) 48
antineoplastic agents - therapeutic use (47) 47
ponatinib (42) 42
middle aged (40) 40
cancer (39) 39
pharmacology & pharmacy (39) 39
adult (37) 37
tyrosine (37) 37
src (36) 36
protein kinase inhibitors - pharmacology (34) 34
animals (33) 33
aniline compounds - adverse effects (32) 32
nitriles - adverse effects (32) 32
quinolines - adverse effects (32) 32
bcr-abl (31) 31
hemic and lymphatic diseases (31) 31
resistance (31) 31
aniline compounds - therapeutic use (30) 30
follow-up (30) 30
imatinib mesylate (30) 30
nitriles - therapeutic use (30) 30
quinolines - therapeutic use (30) 30
safety (30) 30
ski-606 (30) 30
research (29) 29
kinases (27) 27
protein kinase inhibitors - adverse effects (27) 27
quinolines - pharmacology (27) 27
aniline compounds - pharmacology (26) 26
cml (26) 26
nitriles - pharmacology (26) 26
chronic-phase (25) 25
treatment outcome (25) 25
aged (24) 24
analysis (24) 24
drug therapy (24) 24
protein-tyrosine kinases - antagonists & inhibitors (24) 24
aniline compounds - administration & dosage (23) 23
antineoplastic agents - adverse effects (23) 23
antineoplastic agents - pharmacology (23) 23
care and treatment (23) 23
in-vitro (23) 23
medicine & public health (23) 23
nitriles - administration & dosage (23) 23
pyrimidines - therapeutic use (23) 23
quinolines - administration & dosage (23) 23
young adult (23) 23
protein kinase inhibitors - administration & dosage (21) 21
mutation (20) 20
src-family kinases - antagonists & inhibitors (20) 20
therapy (20) 20
antineoplastic agents - administration & dosage (19) 19
dosage and administration (19) 19
patients (19) 19
pharmacokinetics (19) 19
aged, 80 and over (18) 18
article (18) 18
drug resistance, neoplasm (18) 18
efficacy (18) 18
hematology, oncology and palliative medicine (18) 18
piperazines - therapeutic use (18) 18
aniline compounds - pharmacokinetics (17) 17
cells (17) 17
mice (17) 17
nitriles - pharmacokinetics (17) 17
quinolines - pharmacokinetics (17) 17
benzamides (16) 16
clinical trials as topic (16) 16
kinase inhibitor (16) 16
philadelphia chromosome (16) 16
cytogenetic responses (15) 15
fusion proteins, bcr-abl - genetics (15) 15
intolerance (15) 15
adolescent (14) 14
fusion proteins, bcr-abl - antagonists & inhibitors (14) 14
review (14) 14
tyrosine kinase (14) 14
cell line, tumor (13) 13
health aspects (13) 13
imatinib-resistant (13) 13
inhibitor (13) 13
internal medicine (13) 13
leukemia, myeloid, chronic-phase - drug therapy (13) 13
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (271) 271
French (3) 3
Japanese (2) 2
Polish (2) 2
Russian (2) 2
Czech (1) 1
Portuguese (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Heterocycles, ISSN 0385-5414, 2016, Volume 92, Issue 10, pp. 1882 - 1887
New and improved synthetic route of tivozanib is described on a hectogram scale. An reduction cyclization process to prepare the key intermediate... 
CHEMISTRY, ORGANIC | KINASE INHIBITORS | BOSUTINIB
Journal Article
Neuroscience, ISSN 0306-4522, 2015, Volume 304, pp. 316 - 327
Highlights • Pre-plaque changes of systemic inflammatory markers. • Early communication between brain and blood immunity. • TKIs in early pre-plaque Aβ stages... 
Neurology | plaque | inflammation | nilotinib | CX3CL1 | bosutinib
Journal Article
Stroke, ISSN 0039-2499, 11/2017, Volume 48, Issue 11, pp. 3108 - 3116
Journal Article
Nature reviews. Drug discovery, ISSN 1474-1776, 07/2017, Volume 16, Issue 8, p. 530
Journal Article
Leukemia Research, ISSN 0145-2126, 03/2019, Volume 78, pp. 36 - 44
In chronic myeloid leukemia (CML), resistance against second-generation tyrosine kinase inhibitors (TKI) remains a serious clinical challenge, especially in... 
BCR-ABL1 T315I | Drug combinations | Drug resistance | Bosutinib
Journal Article
Leukemia Research, ISSN 0145-2126, 03/2019, Volume 78, pp. 36 - 44
In chronic myeloid leukemia (CML), resistance against second-generation tyrosine kinase inhibitors (TKI) remains a serious clinical challenge, especially in... 
BCR-ABL1 T315I | Drug combinations | Drug resistance | Bosutinib
Journal Article
Heterocycles, ISSN 0385-5414, 2014, Volume 89, Issue 8, pp. 1885 - 1891
New and improved synthetic route of bosutinib intermediate 7-(3-chloropropoxy)-6-methoxy-4-oxo-1,4-dihydroquinoline-3-carbonitrile (3) is described on a... 
Bosutinib Intermediate | Intramolecular Cyclization | New Synthetic Process | BOSUTINIB | IMATINIB | CHEMISTRY, ORGANIC | SKI-606 | KINASE INHIBITOR
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 03/2019, Volume 129, Issue 3, p. 1167
Local flow patterns determine the uneven distribution of atherosclerotic lesions. This research aims to elucidate the mechanism of regulation of nuclear... 
Protein tyrosine kinase | Phosphorylation | Transcription factors | Research | Translocation (Genetics) | Endothelium | Nilotinib | Tyrosine | Atherosclerosis | Development and progression | Bosutinib | Integrins
Journal Article
Acta Haematologica Polonica, ISSN 0001-5814, 10/2017, Volume 48, Issue 4, pp. 274 - 281
Tyrosine kinases inhibitors (TKIs) are the mainstay of chronic myeloid leukemia (CML) treatment. The choice of a specific TKI depends on its side effects,... 
Myelogenous | Chronic | Leukemia | Bosutinib | BCR-ABL Positive
Journal Article
Current Medical Research and Opinion, ISSN 0300-7995, 09/2019, Volume 35, Issue 9, pp. 1615 - 1622
Objective: In clinical trials of second-line therapies for chronic phase chronic myeloid leukemia (CP-CML), to date, only single-arm trials have been conducted... 
chronic-phase | dasatinib | Chronic myeloid leukemia | nilotinib | bosutinib | MEDICINE, RESEARCH & EXPERIMENTAL | MEDICINE, GENERAL & INTERNAL | FOLLOW-UP
Journal Article
Biological and Pharmaceutical Bulletin, ISSN 0918-6158, 2018
Ponatinib, a novel tyrosine kinase inhibitor marketed in 2016, is a key drug used for treating chronic myeloid leukemia and Philadelphia chromosome-positive... 
high-performance liquid chromatography equipped with ultraviolet detection method | human plasma concentration | ponatinib | bosutinib
Journal Article
Expert Review of Hematology, ISSN 1747-4086, 08/2016, Volume 9, Issue 8, pp. 781 - 791
Introduction: Since the introduction of tyrosine kinase inhibitors (TKIs) therapy, chronic myeloid leukemia (CML), has moved from a fatal illness to a... 
dasatinib | TKIs | nilotinib | conception | pregnancy | imatinib | ponatinib | Chronic myeloid leukemia | bosutinib
Journal Article
Mediterranean Journal of Hematology and Infectious Diseases, ISSN 2035-3006, 2015, Volume 7, Issue 1, pp. e2015014 - e2015014
The aim of this paper is to outline pharmacotherapy of the 'third-line management of CML' (progressive disease course after sequential TKI drugs). Current... 
RESISTANT | CELLS | INFECTIOUS DISEASES | MANAGEMENT | IMATINIB | BOSUTINIB | HEMATOLOGY | NILOTINIB | CHRONIC MYELOID-LEUKEMIA | Chronic myeloid leukemia (CML), tyrosine kinase inhibitor (TKI) resistance, Bosutinib, Ponatinib, Dasatinib, Nilotinib, Omacetaxine mepussecinate
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.